Tags: Diabetic Peripheral Neuropathy Treatment, DPN, PEA, CBD, Palmitoylethanolamide, Clinical Trial, Cannabis Research Studies, Medicine Debra Kimless,







Novel Water-Solubilized CBD-based Sublingual Tablets Treat Diabetic Neuropathic Pain - Debra Kimless [STX5Y_v29Gl]

Novel Water-Solubilized CBD-based Sublingual Tablets Treat Diabetic Neuropathic Pain - Debra Kimless [STX5Y_v29Gl]

| 1h 28m 28s | Video has closed captioning.

Tags: Diabetic Peripheral Neuropathy Treatment, DPN, PEA, CBD, Palmitoylethanolamide, Clinical Trial, Cannabis Research Studies, Medicine Debra Kimless, MD, presents, "Novel Water-Solubilized CBD-based Sublingual Tablets Treat Diabetic Neuropathic Pain" at CannMed 23. 0:00 Intro 0:12 Disclosures 0:46 CannMed Conference 3:00 Sublingual CBD/PEA for the Treatment of Painful Diabetic Peripheral Neuropathy (DPN) of the Feet 3:58 Current Rx 4:18 Cannabidiol & Palmitoylethanolamide 4:57 Steps to Improve Bioavailability 5:40 Trial Participants 6:12 Pain Response 7:10 Anxiety Response 7:32 Sleep Response 8:07 Randomized, Double-Blind Placebo-Controlled Trial 8:23 Endpoints 8:33 Participants 9:06 Treatments 9:24 Pain Response 11:35 Anxiety 12:05 Sleep 12:18 Patient Global Impression of Change 12:45 Safety 13:12 Summary 15:00 Q&A Prove the hypothesis that the water-solubilized CBD tablets were an effective treatment for Diabetic Neuropathic Pain (pDPN) and submit an IND to the FDA for approval of this novel pain relief therapy. Conducting first a proof-of-concept open label trial (21 days) and then a double blind, placebo controlled randomized trial (28 days) using water-solubilized CBD sublingual tablets for the treatment of diabetic neuropathic pain of the feet (pDPN). Both clinical trials were conducted remotely using a web-based platform. The participants completed the trials without leaving their homes. This novel approach was developed and initiated prior to the onset of the pandemic and continued uninterrupted. The goals for both studies were safety, and efficacy of the tablets for the treatment of pDPN, poor sleep, and anxiety, and to assess the patient’s global impression of change (PGIC). Participants who received active drug were taking water solubilized 20mg CBD sublingually three times a day. Learn More about CannMed:

Aired: November 24, 2024

Rating: TV-14

Buy Now:

Problems Playing Video? | Closed Captioning

Learn About Midwifery Today

Blog

Learn About Midwifery Today

Read the Modern Day Midwives Blog and learn more about our bloggers, all experienced midwives.

Read now